Another Study Ties Pioglitazone (Actos) to Bladder Cancer Risk

The saga of whether pioglitazone (Actos) increases risk of bladder cancer took another turn with a new analysis of Medicare data showing an elevated risk compared with two other classes of type 2 diabetes drugs.

Patients taking pioglitazone had an incidence of bladder cancer of 308 per 100,000 person-years versus 204 per 100,000 person-years with dipeptidyl peptidase-4 (DPP-4) inhibitors for an adjusted hazard ratio of 1.57 (95% CI 1.23-2.00) in an "as-treated" analysis, found Elizabeth M. Garry, MPH, of University of North Carolina at Chapel Hill, and colleagues.
The rate with pioglitazone was also higher than for sulfonylureas (231 per 100,000 person-years; adjusted HR 1.32, 95% CI 1.02-1.70), they reported online in Diabetes, Obesity and Metabolism.

http://www.medpagetoday.com/Endocrinology/Diabetes/67194

graham64 wrote:The saga of whether pioglitazone (Actos) increases risk of bladder cancer took another turn with a new analysis of Medicare data showing an elevated risk compared with two other classes of type 2 diabetes drugs.

Patients taking pioglitazone had an incidence of bladder cancer of 308 per 100,000 person-years versus 204 per 100,000 person-years with dipeptidyl peptidase-4 (DPP-4) inhibitors for an adjusted hazard ratio of 1.57 (95% CI 1.23-2.00) in an "as-treated" analysis, found Elizabeth M. Garry, MPH, of University of North Carolina at Chapel Hill, and colleagues.
The rate with pioglitazone was also higher than for sulfonylureas (231 per 100,000 person-years; adjusted HR 1.32, 95% CI 1.02-1.70), they reported online in Diabetes, Obesity and Metabolism.

http://www.medpagetoday.com/Endocrinology/Diabetes/67194

Certainly something to be aware of ...

All the best Jan